Full text

Turn on search term navigation

© 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Triple‐class‐refractory multiple myeloma (MM) describes MM refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. In the Phase IIb STORM study (NCT02336815), oral selinexor plus low‐dose dexamethasone (Sel‐dex) demonstrated a 26.2% overall response rate in triple‐class‐refractory MM. Here, we compare overall survival (OS) of 122 patients with triple‐class‐refractory MM who received Sel‐dex in STORM Part 2 with that of 64 similar patients treated with other available therapies in a Flatiron Health Analytic Database (FHAD) cohort. OS from the date that the patients’ MM became triple‐class‐refractory was longer in STORM versus FHAD, with an unadjusted hazard ratio (HR) of 0.43 (P =  .0002; adjusted HR 0.35 [P  =  .011]). In a subset analysis of highly resistant patients receiving further therapies after their MM first became at least triple‐class‐refractory (i.e., who received Sel‐dex in STORM, n = 64, and non‐Sel‐dex in FHAD, n = 36), the OS was significantly longer in STORM with an unadjusted HR of 0.52 (P = .0331; adjusted HR 0.33 [P = .041]). Within the limits of this analysis, the OS of patients with at least triple‐class‐refractory MM was significantly better with Sel‐dex versus available therapies, suggesting that Sel‐dex may be associated with a meaningful OS benefit in these patients.

Details

Title
Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma
Author
Richardson, Paul G 1   VIAFID ORCID Logo  ; Jagannath, Sundar 2 ; Chari, Ajai 3   VIAFID ORCID Logo  ; Vogl, Dan T 4 ; Dimopoulos, Meletios A 5 ; Moreau, Philippe 6 ; Dingli, David 7 ; Lee‐Jen Wei 8 ; Richter, Joshua 9 ; Biran, Noa 9 ; Siegel, David 9 ; Reichmann, William 10 ; Li, Lingling 10 ; Tang, Shijie 10 ; Jean‐Richard Saint‐Martin 10 ; Joshi, Anita 10 ; Kauffman, Michael 10 ; Shah, Jatin 10 ; Shacham, Sharon 10 ; Lonial, Sagar 11 

 Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana‐Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 
 Mount Sinai Medical Center, New York, New York 
 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 
 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 
 National and Kapodistrian University of Athens School of Medicine, Athens, Greece 
 CHU de Nantes‐Hôtel Dieu, Nantes, France 
 Mayo Clinic, Rochester, Minnesota 
 Harvard T.H. Chan School of Public Health, Boston, Massachusetts 
 Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey 
10  Karyopharm Therapeutics Inc., Newton, Massachusetts, USA 
11  Winship Cancer Institute of Emory University, Atlanta, Georgia, USA 
Pages
48-55
Section
HAEMATOLOGIC MALIGNANCY – PLASMA CELL
Publication year
2021
Publication date
Feb 2021
Publisher
John Wiley & Sons, Inc.
e-ISSN
26886146
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2549527654
Copyright
© 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.